Article | June 16, 2014

Results Of The First Ever REMOTE Clinical Trial

Laurie Meehan

By Laurie Meehan, Polaris Compliance Consultants, Inc.

In the clinical research industry, we’re always evaluating things.  We evaluate drugs and biologics.  We evaluate medical devices.  We also evaluate research techniques.  Yes, we try trials.  We study studies.  That’s what Pfizer was doing when it launched its REMOTE pilot trial in early 2011 – evaluating the effectiveness of a study in which patients participated remotely, without ever having to visit a study site.  How would the results of the REMOTE study compare with those of a similar, completed, conventional study?  Would this innovative research approach be validated?

There were plenty of good reasons for Pfizer to try to answer these questions.  “Virtual” trials would make research participation possible for patients who live far from investigative sites, or for patients who have trouble moving about.  Virtual trials may reduce patient withdrawal rates, as remote access would likely be more convenient and require less of a time commitment from patients.   They also have the potential to save research dollars.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online